Doxycycline monotherapy first line treatment for Chronic Endometritis: Study
Researchers have determined in a new study that doxycycline monotherapy can actually be the first-line therapy of choice for chronic endometritis (CE), as it is as effective as a levofloxacin-tinidazole combination but produces fewer side effects. CE is a chronic inflammation of the endometrium with a low rate of spontaneous cure, necessitating usually antibiotic treatment for improvement. The most commonly employed antibiotic regimens for CE are doxycycline monotherapy or the combination of levofloxacin and tinidazole. This study was published in the American Journal of Obstetrics and Gynecology by Yue Liu and colleagues.
The objective of this study was to compare the efficacy and safety of doxycycline monotherapy with that of levofloxacin co-administered with tinidazole in the treatment of patients diagnosed with CE using CD138 immunohistochemistry.
A parallel randomized controlled trial was conducted, involving 172 CE-diagnosed patients. The patients were divided into two groups after randomization: the intervention group was given levofloxacin together with tinidazole, while the control group was given doxycycline as a single therapy. Follow-up assessment consisted of multiple hysteroscopy and endometrial biopsy during the first proliferative phase of menstruation after treatment, cure being the change of CD138 expression from positive to negative. Rates of cure and rates of adverse reaction were examined by per-protocol and intent-to-treat analysis.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.